Stephen Ratvasky

May 10, 2018

My research focuses on the development of anticancer metallodrugs capable of spatiotemporally controlled therapeutic radical generation. Piggybacking triggerable ligand-based radical generation with metal-based antitumor reactivity has the potential to give metallodrugs with higher potency that can be administered at lower doses than those currently used in the clinic.”

Fun Fact: I have three pet rats, two of which are named after a pair of Nobel prize-winning organic chemists famous for exploring cycloaddition reactions.  Can you guess who?

Degree Program: Inorganic Chemistry

Lab: Zaleski

Undergraduate Institution: Duquesne University